The Sixth Joint Task Force of the European Society of Cardiology (ESC) and Other Societies on Cardiovascular Disease Prevention in Clinical Practice Guidelines have been published in 2016: greater emphasis has been placed on a population-based approach, on disease-specific interventions and on female-specific conditions, younger individuals and ethnic minorities. The ESC guidelines underscore that a lifetime approach to cardiovascular risk is important as both risk and prevention are dynamic and continuous. The guidelines can assist healthcare professionals, patients, and are valuable for the healthcare system but implementation of secondary cardiovascular disease prevention is far from optimal. Although there is no single way to ensure the use of guidelines in practice, multifaceted interventions based on known barriers are most appropriate. Essential components for implementation are: (a) taking action; (b) strengthening capacity; (c) evaluating impact; (d) advancing policy; and (e) engaging in regional and global partnerships. The strategy depends on a balanced investment in all available intervention approaches, from policy and environmental changes designed to prevent risk factors to assurance of quality care for individuals with cardiovascular disease. Our greatest challenges represent our greatest opportunities.
American Heart Association. 2003 Heart and Stroke Statistics – 2003 Update, Dallas, TX: American Heart Association, 2003.
2.
AlwanA. Global status report on noncommunicable diseases 2010, Geneva: World Health Organization, 2011.
3.
World Health Organization. Cardiovascular Diseases, Fact Sheet Number 317, Geneva: WHO, 2009.
4.
PiepoliMFHoesAWAgewallS. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention and Rehabilitation (EACPR). Eur Heart J2016; 37: 2315–2381. DOI: 10.1093/eurheartj/ehw106.
5.
World Health Organization. Scaling up action agains noncommunicable diseases: How much will it cost?, Geneva: WHO, 2011.
6.
ChowCKJollySRao-MelaciniP. Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes. Circulation2010; 121: 750–758.
7.
BramlagePMesserCBitterlichN. The effect of optimal medical therapy on 1-year mortality after acute myocardial infarction. Heart2010; 96: 604–609.
8.
Corrà U and Rauch B. The ESC Textbook of Preventive Cardiology. In: Gielen S, De Backer G, Piepoli M, et al. (eds) Setting and delivery of preventive cardiology. Acute care, immediate secondary prevention, and referral. Oxford: Oxford University Press, 2015, pp. 278–284.
9.
KotsevaKWoodDDe BackerG. EUROASPIRE Study Group. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil2009; 16: 121–137.
10.
AndrikopoulosGTzeisSNikasN. Short-term outcome and attainment of secondary prevention goals in patients with acute coronary syndrome – results from the countrywide TARGET study. Int J Cardiol2013; 168: 922–927.
11.
PiepoliMFCorràUAbreuA. Cardiac Rehabilitation Section of the European Association for Cardiovascular Prevention and Rehabilitation of the ESC. Challenges in secondary prevention of cardiovascular diseases: a review of the current practice. Int J Cardiol2015; 180: 114–119. DOI: 10.1016/j.ijcard.2014.11.107.
12.
PiepoliMFCorraUBenzerW. Secondary prevention through cardiac rehabilitation: from knowledge to implementation. A position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation. Eur J Cardiovasc Prev Rehabil2010; 17: 1–17.
13.
PiepoliMFCorràUAdamopoulosS. Secondary prevention in the clinical management of patients with cardiovascular diseases. Core components, standards and outcome measures for referral and delivery: a policy statement from the cardiac rehabilitation section of the European Association for Cardiovascular Prevention and Rehabilitation. Endorsed by the Committee for Practice Guidelines of the European Society of Cardiology. Eur J Prev Cardiol2014; 21: 664–681.
14.
AndersonLTaylorRS. Cardiac rehabilitation for people with heart disease: an overview of Cochrane systematic reviews. Cochrane Database Syst Rev2014; 12: CD011273–CD011273.
15.
WoolfSGrolRHutchinsonAThe potential benefits, limitations and harms of clinical guidelines. In: EcclesMGrimshawJ (eds). Clinical Guidelines. From Conception to Use, Oxford: Radcliffe Medical Press Ltd, 2000, pp. 19–29.
16.
PayneM. How to kill a unicorn. How the world’s hottest innovation factory builds bold ideas that make it to market, 1st ed. New York: Crown Business, 2014.
17.
FederGEcclesMGrolRUsing clinical guidelines. In: EcclesMGrimshawJ (eds). Clinical Guidelines. From Conception to Use, Oxford: Radcliffe Medical Press Ltd, 2000, pp. 85–100.
18.
EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events. Eur Heart J1997; 18: 1569–1582.
19.
EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J2001; 22: 554–572.
20.
KotsevaKWoodDDe BackerG. EUROASPIRE Study Group. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet2009; 373: 929–940.
21.
KotsevaKWoodDDe BacquerD. EUROASPIRE Investigators. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol2016; 23: 636–648.
22.
PhillipsLSBranchWTCookCB. Clinical inertia. Ann Intern Med2001; 135: 825–834.
23.
CabanaMSandCPoweN. Why don’t physicians follow clinical practice guidelines? A framework for improvement. JAMA1999; 15: 1458–1465.
24.
SaffordMMShewchukRQuH. Reasons for not intensifying medications: differentiating ‘clinical inertia’ from appropriate care. J Gen Intern Med2007; 22: 1648–1655.
Evaluation Strategies & Tools. The American Heart Association's Get With The GuidelinesSM (GWTG). Impact: AHA “Get With The Guidelines”. Available at: americanheart.newmediagateway.com (accessed 1 March 2017).
27.
US Department of Health and Human Services Centers for Disease Control and Prevention. A public health action plan to prevent heart disease and stroke. American Heart Association, Fighting heart disease and stroke. US Department of Health and Human Services Centers for Disease Control and Prevention.
28.
MaddoxTMHoPM. Health care research in improving the delivery of care for patients with cardiovascular disease. Moving from observation to innovation to action. Circulation2017; 135: 403–405.
